Company profile: VectorBuilder
1.1 - Company Overview
Company description
- Provider of an online platform for vector cloning and CRO services, including gene delivery design, development and optimization, vector customization, and clinical vector preparation. Offers custom vector design and cloning (plasmids, lentivirus, AAV), viral vector packaging, stable cell line engineering, mutation library construction, AAV capsid evolution, and drug-selection markers.
Products and services
- Stable Cell Line Engineering: Constructs CRISPR-based stable cell lines with defined genetic edits using CRISPR and other techniques, incorporating antibiotic selection and cell sorting to isolate desired clones
- Vector Design and Cloning: The online platform custom-engineered to architect and construct plasmids, lentivirus, AAV, and other viral vectors, enabling gene delivery design, development and optimization with scientific research-specific customization
- Viral Vector Packaging: Produces high-purity packaging of lentivirus, AAV, adenovirus, and more, delivering validated high titer and purity specifications for downstream gene delivery experiments and applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to VectorBuilder
Hammersmith Medicines Research
HQ: United Kingdom
Website
- Description: Provider of contract research services for phase 1 and early phase 2 clinical trials, including volunteer recruitment, trial design, data management and statistical analysis. Offers laboratory services (biomarker assays, DNA extraction/PCR, flow cytometry, ELISA), pharmacy manufacturing (sterile/non-sterile, radiopharmaceuticals), QA and regulatory compliance (GMP, ISO 27001), and accredited COVID-19 testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hammersmith Medicines Research company profile →
Cellipont
HQ: United States
Website
- Description: Provider of cell therapy CDMO services specializing in cell therapy development and small-to-large batch production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellipont company profile →
Lotus Clinical Research
HQ: United States
Website
- Description: Provider of full-service CRO services and a network of 20+ wholly-owned US clinical research sites for analgesic programs and trials in psychiatry, neurology, pain, and addiction. Services include project management, site selection and monitoring, EDC and data management, biostatistics, medical monitoring, medical writing, quality operations, placebo response mitigation, global rater training, scientific consultation, and metabolic disease trial support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lotus Clinical Research company profile →
Ventus Therapeutics
HQ: United States
Website
- Description: Provider of novel small molecule medicines targeting the innate immune system to treat autoimmune and inflammatory diseases and cancer. Offers VENT-03, a first-in-class oral cGAS inhibitor in Phase 1; VENT-02, a brain-penetrant NLRP3 inhibitor in Phase 1 for neuro-inflammation and neurodegeneration; and ReSOLVE, a structural biology and computational chemistry platform for small molecule drug discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ventus Therapeutics company profile →
Lucy Scientific
HQ: Canada
Website
- Description: Provider of research, development, and manufacturing of controlled psychotropic drugs, offering targeted formulations, single molecule fractions, crude extracts, raw materials, and white- and private-label products to support mental research and the creation of psychotropic and psychedelic therapeutics across organic, synthetic, and biosynthetic categories.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lucy Scientific company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for VectorBuilder
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to VectorBuilder
2.2 - Growth funds investing in similar companies to VectorBuilder
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for VectorBuilder
4.2 - Public trading comparable groups for VectorBuilder
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →